{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-100532","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2026-08-25T11:15:43+00:00","discovered_at":"2026-08-25T11:20:03.853776+00:00","generated_at":"2026-08-25T11:20:10.051642+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"BioXcel gets $1.25M loan, liquidity covenant cut to $250K, must close deal by Aug 31","bullets":["Oaktree lenders advanced $1.25M term loan; BioXcel paid $250K upfront fee (20% of principal).","Minimum liquidity covenant reduced from $3.0M to $250K under Fourteenth Amendment.","Company must sign definitive agreements by Aug 31, 2026 for full repayment or alternative capital solution.","Covenants amended to remove flexibility for out-licensing IP and asset sales.","Amendment includes plan support provisions for potential insolvency proceedings."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-100532","json":"https://secwatch.observer/filing/0001104659-26-100532.json","markdown":"https://secwatch.observer/filing/0001104659-26-100532.md","text":"https://secwatch.observer/filing/0001104659-26-100532.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926100532/0001104659-26-100532-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926100532/tm2623945d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-25T11:20:10.051642+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}